Experts Address Ethical, Legal and Insurance Issues Surrounding CRISPR Gene Editing Technology

Christiana Care Health System and Delaware Biotechnology Association Symposium Opens Dialogue about CRISPR

Article ID: 696058

Released: 13-Jun-2018 10:00 AM EDT

Source Newsroom: Christiana Care Health System

Expert Pitch
  • Eric Kmiec, Ph.D., director of the Gene Editing Institute of the Helen F. Graham Cancer Center & Research Institute at Christiana Care Health System

  • Speakers at the CRISPR 360 Gene Editing Symposium. From left: Bob Oakes, Esq., patent attorney with Fish & Richardson, Mark Greene, Ph.D., Research Director at the Center for Science, Ethics & Public Policy at the University of Delaware, Debra J. H. Mathews, Ph.D., MA, Assistant Director for Science Programs for the Johns Hopkins Berman Institute of Bioethics and Associate Professor in the Department of Pediatrics, Johns Hopkins University School of Medicine, Edmund Pezalla, M.D., MPH, Ph.D., Founder and CEO of Enlightenment Bioconsult, Eric Kmiec, Ph.D., Director of the Gene Editing Institute of Christiana Care’s Helen F. Graham Cancer Center & Research Institute and Helen Stimson, president and CEO of the Delaware BioScience Association

Newswise — Wilmington, Delaware, June 12, 2018 ­— The subject of TV news programs and magazine headlines, CRISPR gene editing technology is spearheading a biomedical revolution. Scientists are working to alter mosquito DNA to prevent malaria and modify pig organs for human transplant. The Gene Editing Institute of Christiana Care Health System is researching the use of CRISPR in lung cancer treatments.

But who owns CRISPR and its related technologies? Will insurance pay for gene editing procedures


Comment/Share





Chat now!